- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
QBI Life Sciences uses Nanotechnology to advance Drug Discovery
Madison, WI | August 10, 2005
Long interested in advancing the process of discovering new treatments for human diseases, the principals of QBI Life Sciences today announced the release of a second polymeric micelle product, PreserveX™-QML-B Polymeric Micelles. PreserveX™ Polymeric Micelles, useful in working with difficult to handle proteins average 21 nanometers in diameter. In the presence of native cell membrane fractions, PreserveX™ Polymeric Micelles self-assemble embedding pieces of cellular membranes in the complex creating multiple particles each providing an environment similar to that of the native membrane. Below is an illustration of this process.
This graphic illustrates the use of PreserveX™ Polymeric Micelles to solubilize membrane proteins and associated lipids from membrane fractions resulting in stabilized micelle/protein/lipid complexes.
Copyright © QBI Life Sciences
The newly released product, PreserveX™-QML-B Polymeric Micelles contains a biotin label enabling the placement of the micelle/protein/lipid complex onto a solid support such as a protein microarray. Below is an illustration of complexes immobilized on a solid support.
This graphic illustrates the use of PreserveX™-QML-B to immobilize the biotin-labeled micelle/protein/lipid complexes on a surface (bar at the bottom of the graphic) with the use of streptavidin. Once immobilized, ligand binding or enzymatic activity can be determined, or the presence of the protein can be confirmed.
Copyright © QBI Life Sciences
PreserveX™ Polymeric Micelles reflect the combination of polymer chemistry technologies with protein chemistry technologies. Vladimir Trubetskoy, Ph.D., Director of Polymer Chemistry has headed up a team at QBI Life Sciences to develop polymer nano-particles that are useful in working with some of the most difficult to handle proteins. Focusing on membrane proteins (those proteins that reside on, near or embedded in cellular membranes), Dr. Trubetskoy and his team of scientists have come up with a set of very valuable drug discovery tools. In the area of human health, membrane proteins represent 70% of all known drug targets, the agents inside the human body upon which drugs evoke a therapeutic effect. To date, efforts to study these proteins and develop drugs targeting these proteins have been limited.
Announcement of the introduction of PreserveX™-QML-B is coincident with a presentation of product performance at the 2005 Drug Discovery Technology® & Development World Congress in Boston, Massachusetts (link).
About QBI Life Sciences:
QBI Life Sciences is a division of Quintessence Biosciences, Inc. QBI Life Sciences is focused on development and supply of research tools focused on work with membrane proteins. The aim of the Company’s product development efforts is to enable new areas of research.
For more information, please visit www.qbilifesci.comMedia Contact:
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
First multicellular organism inspires the design of better cancer drugs September 15th, 2016
A versatile method to pattern functionalized nanowires: A team of researchers from Hokkaido University has developed a versatile method to pattern the structure of 'nanowires,' providing a new tool for the development of novel nanodevices September 9th, 2016
Location matters in the self-assembly of nanoclusters: Iowa State University scientists have developed a new formulation to explain an aspect of the self-assembly of nanoclusters on surfaces that has broad applications for nanotechnology September 8th, 2016
Fast, efficient sperm tails inspire nanobiotechnology December 5th, 2016
UTSA study describes new minimally invasive device to treat cancer and other illnesses: Medicine diffusion capsule could locally treat multiple ailments and diseases over several weeks December 3rd, 2016
Nanobiotix Provides Update on Global Development of Lead Product NBTXR3: Seven clinical trials across the world: More than 2/3 of STS patients recruited in the “act.in.sarc” Phase II/III trial: Phase I/II prostate cancer trial now recruiting in the U.S. November 28th, 2016
Leti IEDM 2016 Paper Clarifies Correlation between Endurance, Window Margin and Retention in RRAM for First Time: Paper Presented at IEDM 2016 Offers Ways to Reconcile High-cycling Requirements and Instability at High Temperatures in Resistive RAM December 6th, 2016
Infrared instrumentation leader secures exclusive use of Vantablack coating December 5th, 2016